Renovaro Biosciences Inc. – NASDAQ:RENB
Renovaro Biosciences stock price today
Renovaro Biosciences stock price monthly change
Renovaro Biosciences stock price quarterly change
Renovaro Biosciences stock price yearly change
Renovaro Biosciences key metrics
Market Cap | 229.34M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRenovaro Biosciences stock price history
Renovaro Biosciences stock forecast
Renovaro Biosciences financial statements
| 2016 | 42.76K | -1.73M | -4057.24% |
|---|---|---|---|
| 2018 | 0 | -6.31M | |
| 2021 | 0 | -26.72M | |
| 2024 | 0 | -80.65M |
| 2014 | 5239909 | 1.75M | 33.54% |
|---|---|---|---|
| 2016 | 870831 | 1.50M | 173.19% |
| 2018 | 182502456 | 23.76M | 13.02% |
| 2024 | 163129450 | 31.15M | 19.1% |
| 2018 | -4.33M | -575.73K | 16.71M |
|---|---|---|---|
| 2020 | -10.45M | -184.46K | 7.2M |
| 2023 | -11.77M | -29.77K | 4.51M |
| 2024 | -10.97M | -1.26M | 10.51M |
Renovaro Biosciences alternative data
| Nov 2023 | 12 |
|---|---|
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 12 |
| Jun 2024 | 12 |
| Jul 2024 | 12 |
| Dec 2024 | 25 |
Renovaro Biosciences other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2024 | 0 | 134671 |
| Jul 2024 | 0 | 204553 |
-
What's the price of Renovaro Biosciences stock today?
One share of Renovaro Biosciences stock can currently be purchased for approximately $0.23.
-
When is Renovaro Biosciences's next earnings date?
Unfortunately, Renovaro Biosciences's (RENB) next earnings date is currently unknown.
-
Does Renovaro Biosciences pay dividends?
No, Renovaro Biosciences does not pay dividends.
-
How much money does Renovaro Biosciences make?
Renovaro Biosciences has a market capitalization of 229.34M.
-
What is Renovaro Biosciences's stock symbol?
Renovaro Biosciences Inc. is traded on the NASDAQ under the ticker symbol "RENB".
-
What is Renovaro Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Renovaro Biosciences?
Shares of Renovaro Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Renovaro Biosciences have?
As Dec 2024, Renovaro Biosciences employs 25 workers, which is 108% more then previous month and 108% more then previous quarter.
-
When Renovaro Biosciences went public?
Renovaro Biosciences Inc. is publicly traded company for more then 7 years since IPO on 7 Feb 2018.
-
What is Renovaro Biosciences's official website?
The official website for Renovaro Biosciences is renovarobio.com.
-
Where are Renovaro Biosciences's headquarters?
Renovaro Biosciences is headquartered at 2080 Century Park East, Los Angeles, CA.
-
How can i contact Renovaro Biosciences?
Renovaro Biosciences's mailing address is 2080 Century Park East, Los Angeles, CA and company can be reached via phone at +30 59181980.
Renovaro Biosciences company profile:
Renovaro Biosciences Inc.
renovarobio.comNASDAQ
25
Biotechnology
Healthcare
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.
Los Angeles, CA 90067
CIK: 0001527728
ISIN: US29350E1047
:
